Akorn fights to salvage Fresenius deal in appeal to Delaware Supreme Court

courthouse
Fresenius abandoned its Akorn merger in April, prompting a lawsuit from the latter drugmaker. (Pixabay)

Akorn, desperate to cling to its now-abandoned buyout by Fresenius, has taken its case for the deal to Delaware Supreme Court. Its argument? The lower court judge who said Fresenius bagged the deal legally didn't follow a legal standard in making that decision.

In Akorn’s appeal, lawyers contend Fresenius knew about the risks of the $4.3 billion deal at the time of signing last year, and that Delaware Vice Chancellor J. Travis Laster made his decision based on “personal guesswork and intuition.”

The drugmaker hopes to force Fresenius to follow through with the deal, while Fresenius maintains it had every right to end the merger.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Fresenius' case for nixing the deal: Data integrity issues cropped up at Akorn since their agreement, and Akorn's stock price fell nearly 80% from 2017 highs as the problems went public. Fresenius had agreed to pay $34 per share for Akorn, and its stock now stands at about $5.50 per share.

“Every investigator who looked at this company, every time you picked up a rock, you saw more problems,” Fresenius’ lawyer said, going on to cite the precipitous drop in its stock price. Akorn didn’t try to demonstrate at trial that the business would turn around, Fresenius lawyers said.

RELATED: Judge frees Fresenius from buyout, citing 'extensive and recurring' data problems at Akorn

When Fresenius struck the buyout, it touted the acquisition as a “strategically complementary combination” that would diversify its portfolio and expand its sterile manufacturing capacity. The buy would add three U.S. manufacturing sites to Fresenius' network, plus another in India, and about 2,000 employees.

Soon after, however, the companies said they were looking into whether Akorn had violated FDA development standards, and Fresenius said in April it would walk away from the buy. Akorn said the investigation had “not found any facts that would result in a material adverse effect on Akorn’s businesses and therefore there is no basis to terminate the transaction.”

RELATED: Fresenius dumps its $4.3B Akorn buyout, and a 'legal battle royale' could come next

Akorn sued, and the case went to trial in July. In October, the trial court judge ruled Fresenius had fulfilled its contractual obligations and acted legally when it terminated the merger.

After the trial, Laster wrote that “extensive and recurring quality and data integrity problems at Akorn convinced me that Akorn did not have a well-functioning quality system and lacked a meaningful culture of compliance.”

 

Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.